CDK2 and breast carcinoma: Herrera-Abreu et al. demonstrate in a study from 2016 that cyclin E1 is upregulated via CDK2 activation in palbociclib-resistant cells (that were generated via chronic exposure to the drug and named palbociclib-resistant MCF-7 breast cancer cells) [27].